Extended Data Fig. 4: BNT162b2-induced antibody responses.

Vaccination schedule and serum sampling are described in Extended Data Fig. 1. Participants were immunized with BNT162b2 on day 1 and day 22 (n = 12 per dose cohort; from day 22 onwards n = 11 for the 1-μg and 10-μg dose cohorts). Arrowheads indicate days of vaccination. Pre-dose responses across all dose levels were combined. Samples from individuals who had been infected with SARS-CoV-2 or had recovered from COVID-19 (HCS) (n = 38) were obtained at least 14 days after PCR-confirmed diagnosis and at a time at which the donors were no longer symptomatic. a–d, Each serum was tested in duplicate and IgG GMCs (a, c) and geometric mean 50% (pseudo)neutralizing titres (GMTs) (c, d) were plotted. For values below the LLOQ (1.27 (S1 IgG), 1.15 (RBD IgG) (a), 20 (VNT₅₀) (c) and 300 (pVNT₅₀) (d)), LLOQ/2 values were plotted. a, Recombinant S1- and RBD-binding IgG group GMCs (values above bars) with 95% confidence intervals. b, Fraction of participants with ≥4-fold-increased 50% serum neutralizing response above baseline (from Fig. 1a) at each time point. Fractions with exact 95% Clopper–Pearson confidence intervals. c, Non-parametric Spearman correlation of recombinant S1-binding IgG GMCs (from a) with VNT₅₀ from day 29 sera (from Fig. 1a) with data points for participants with GMCs and GMTs below the LLOQ (open circles) excluded. d, pVNT₅₀ across a pseudovirus panel displaying 19 SARS-CoV-2 S variants on a Wuhan-Hu-1 strain background, including 18 with RBD single-nucleotide-exchange mutations and the dominant D614G variant (1-, 10- and 30-μg dose cohorts, n = 1 or 2 representative sera each; day 29).